Didanosine
- Generic Name
- Didanosine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12N4O3
- CAS Number
- 69655-05-6
- Unique Ingredient Identifier
- K3GDH6OH08
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.
- Indication
For use, in combination with other antiretroviral agents, in the treatment of HIV-1 infection in adults.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002240
- Locations
- 🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Albany Med College, Albany, New York, United States
🇺🇸Clinsites / Sorra Research Ctr, Birmingham, Alabama, United States
Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-04-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 120
- Registration Number
- NCT00002224
- Locations
- 🇺🇸
Chicago Ctr for Clinical Research, Chicago, Illinois, United States
🇺🇸Univ of Kansas School of Medicine, Wichita, Kansas, United States
🇺🇸Beacon Clinic / Boulder Community Hosp, Boulder, Colorado, United States
A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-04-25
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002411
- Locations
- 🇺🇸
Northwestern Univ / Div of Infect Diseases, Chicago, Illinois, United States
🇺🇸Rush Presbyterian / ST Lukes Med Ctr, Chicago, Illinois, United States
🇺🇸Univ of Texas / Med Branch at Galveston, Galveston, Texas, United States
A Comparison of Two Dose Levels of Didanosine Used in Combination With Stavudine in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-04-25
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002207
- Locations
- 🇺🇸
ID Care Inc, Somerville, New Jersey, United States
🇺🇸Fanno Creek Clinic, Portland, Oregon, United States
🇺🇸Dr Iraj Mirshahi, Richmond, Virginia, United States
A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002176
- Locations
- 🇺🇸
Univ of California at San Francisco Gen Hosp, San Francisco, California, United States
A Study Comparing Two Forms of Didanosine in HIV-infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT00002360
A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002177
- Locations
- 🇺🇸
Univ of California at San Francisco Gen Hosp, San Francisco, California, United States
A Study of Azidothymidine in HIV-Infected Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-14
- Target Recruit Count
- 75
- Registration Number
- NCT00000982
- Locations
- 🇺🇸
Walter Reed / USUHS / Pediatrics, Bethesda, Maryland, United States
🇺🇸Children's Hosp at Albany Med Ctr, Albany, New York, United States
🇺🇸Univ of Florida Med Ctr, Jacksonville, Florida, United States
Comparison of ddI Versus Zidovudine in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-14
- Target Recruit Count
- 1500
- Registration Number
- NCT00000979
- Locations
- 🇺🇸
Whitman - Walker Clinic, Washington, District of Columbia, United States
🇺🇸Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States
🇺🇸Med Ctr of Central Massachusetts, Worcester, Massachusetts, United States
A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-02
- Target Recruit Count
- 74
- Registration Number
- NCT00001122
- Locations
- 🇺🇸
UCSD, San Diego, California, United States
🇺🇸Univ of Texas Southwestern Med Ctr, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.